angiotensin-i and Pulmonary-Arterial-Hypertension

angiotensin-i has been researched along with Pulmonary-Arterial-Hypertension* in 3 studies

Reviews

1 review(s) available for angiotensin-i and Pulmonary-Arterial-Hypertension

ArticleYear
Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1-7)-Mas Axis in Pulmonary Arterial Hypertension.
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:2

    Pulmonary arterial hypertension (PAH) is a progressive disease with a complex aetiology and high mortality. Functional and structural changes in the small pulmonary arteries lead to elevated pulmonary arterial pressure, resulting in right heart failure. The pathobiology of PAH is not fully understood, and novel treatment targets in PAH are desperately needed. The renin-angiotensin system is critical for maintaining homeostasis of the cardiovascular system. The system consists of the angiotensin converting enzyme (ACE)-angiotensin (Ang) II-angiotensin type 1 receptor (AT

    Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Humans; Peptide Fragments; Peptidyl-Dipeptidase A; Pulmonary Arterial Hypertension; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Renin-Angiotensin System

2022

Other Studies

2 other study(ies) available for angiotensin-i and Pulmonary-Arterial-Hypertension

ArticleYear
Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertension.
    The European respiratory journal, 2020, Volume: 56, Issue:1

    In animal models of pulmonary arterial hypertension (PAH), angiotensin-converting enzyme (ACE)2 and angiotensin (Ang)-(1-7) have been shown to have vasodilatory, antiproliferative, antifibrotic and antihypertrophic properties. However, the status and role of the ACE2-Ang(1-7) axis in human PAH is incompletely understood.. We studied 85 patients with a diagnosis of PAH of distinct aetiologies. 55 healthy blood donors paired for age and sex served as controls. Blood samples were obtained from the pulmonary artery in patients with PAH during right heart catheterisation. Peripheral blood was obtained for both groups. Ang(1-7) and -II were measured using zone capillary electrophoresis. Aldosterone, Ang(1-9), AngA and ACE2 were measured using ELISA, and ACE2 activity was determined enzymatically.. Of the 85 patients, 47 had idiopathic PAH, 25 had PAH associated with congenital heart disease and 13 had PAH associated with collagen vascular disease. Compared to controls, patients with PAH had a higher concentration of AngII (median 1.03, interquartile range 0.72-1.88 pmol·mL. The AngII-ACE2-Ang(1-7) axis appears to be altered in human PAH and we propose that this imbalance, in favour of AngII, plays a role in the pathogenesis of the severe PAH. Further mechanistic studies are warranted.

    Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Humans; Peptide Fragments; Peptidyl-Dipeptidase A; Pulmonary Arterial Hypertension

2020
Lung ACE2 and ADAM17 in pulmonary arterial hypertension: Implications for COVID-19?
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020, Volume: 39, Issue:10

    Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Peptide Fragments; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pulmonary Arterial Hypertension; SARS-CoV-2

2020